会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 65. 发明申请
    • TREATMENT OF NON-PROLIFERATIVE CYSTIC DISEASE
    • 非增殖性疾病的治疗
    • WO2012074559A2
    • 2012-06-07
    • PCT/US2011001954
    • 2011-12-02
    • UNIV NEW YORKKLEINBERG DAVID L
    • KLEINBERG DAVID L
    • A61K39/395A61K38/31A61P35/00C12Q1/02G01N33/573
    • G01N33/5011A61K38/12A61K38/16A61K38/31G01N33/5088G01N33/57415G01N2800/365
    • The present invention relates generally to the treatment of non-proliferative cystic disease of the breast. More particularly, the present invention relates generally to the treatment of non-proliferative cystic disease of the breast in BRCA1 mutant carriers. Accordingly, the invention relates to the use and application of compounds or agents, including somatostatin analogs, that inhibit insulin-like growth factor I (IGF-I) or insulin-like growth factor I receptor signaling for the treatment of non-proliferative cystic disease of the breast. The invention further relates to the use and application of these compounds or agents for the treatment of non-proliferative cystic disease of the breast in BRCA1 patients. The invention also relates to use of somatostatin analog SOM230 in treatment of non-proliferative cystic disease of the breast and more particularly, to use of somatostatin analog SOM230 in treatment of BRCA1 associated non-proliferative cystic disease.
    • 本发明一般涉及乳腺非增生性囊性疾病的治疗。 更具体地说,本发明一般涉及BRCA1突变体携带者乳腺非增殖性囊性疾病的治疗。 因此,本发明涉及抑制胰岛素样生长因子I(IGF-I)或胰岛素样生长因子I受体信号传导治疗非增殖性囊性疾病的化合物或试剂(包括生长抑素类似物)的用途和应用 的乳房 本发明还涉及这些化合物或药剂在BRCA1患者中用于治疗乳腺非增殖性囊性疾病的用途和应用。 本发明还涉及生长抑素类似物SOM230在治疗乳腺非增殖性囊性疾病中的用途,更具体地说,涉及使用生长抑素类似物SOM230来治疗BRCA1相关的非增殖性囊性疾病。